肌层浸润性膀胱癌围手术期剂量密集甲氨蝶呤、长春碱、多柔比星与顺铂治疗(VESPER):开放标签随机3期研究5年生存终点
VESPER研究在法国28家大学医院或综合癌症中心纳入493例肌层浸润性尿路上皮癌患者,随机接受围手术期dd-MVAC或GC方案。5年随访时,围手术期总体人群中dd-MVAC组总生存与GC组无显著差异,但dd-MVAC组膀胱癌死亡累积发生率低于GC组;新辅助亚组中dd-MVAC组总生存改善且膀胱癌死亡时间延长。
要点
- 围手术期总体人群中dd-MVAC组5年总生存64% vs GC组56%,HRstrat 0·79(95%CI 0·59-1·05)。
- dd-MVAC组5年膀胱癌死亡累积发生率27% vs GC组40%,HRstrat 0·61(95%CI 0·45-0·84)。
- 新辅助亚组dd-MVAC组5年总生存66% vs GC组57%,HR 0·71(95%CI 0·52-0·97)。
核心结论
- 5年总生存结果与主要终点(3年无进展生存)分析一致;围手术期总体人群中未发现dd-MVAC较GC改善总生存的证据,但数据支持在新辅助治疗中使用6周期dd-MVAC而非4周期GC。
- 作者认为这些结果应影响膀胱癌的临床实践及未来的免疫治疗试验。
研究设计与样本
- VESPER为开放标签、随机、3期试验,在法国28家大学医院或综合癌症中心开展。
- 纳入年龄≤18岁且≤80岁、原发膀胱癌且组织学确诊肌层浸润性尿路上皮癌的成人患者,按1:1随机(区组大小4)分配至dd-MVAC(每2周,共6周期)或GC(每3周,共4周期)。
- 2013年2月25日至2018年3月1日共随机500例,最终意向治疗(ITT)人群493例:GC组245例(50%)、dd-MVAC组248例(50%);男性408例(83%)、女性85例(17%);437例(89%)接受新辅助化疗。
- 总生存采用Kaplan-Meier法、按化疗给药方式(新辅助或辅助)和淋巴结受累分层的log-rank检验比较;膀胱癌死亡时间采用竞争风险Aalen模型及Fine和Gray回归模型(分层因素相同)。
- 中位随访5·3年(IQR 5·1-5·4),5年截点时报告190例死亡;试验注册号ClinicalTrials.gov NCT01812369,已完成。
主要发现
- 围手术期总体ITT人群5年总生存:dd-MVAC组64%(95%CI 58-70)vs GC组56%(95%CI 50-63),分层风险比(HRstrat)0·79(95%CI 0·59-1·05),未达统计学显著。
- 膀胱癌死亡时间:dd-MVAC组5年膀胱癌死亡累积发生率27%(95%CI 21-32)vs GC组40%(95%CI 34-46),HRstrat 0·61(95%CI 0·45-0·84)。
- 新辅助亚组5年总生存:dd-MVAC组66%(95%CI 60-73)vs GC组57%(95%CI 50-64),HR 0·71(95%CI 0·52-0·97);膀胱癌死亡时间:dd-MVAC组5年累积发生率24%(95%CI 18-30)vs GC组38%(95%CI 32-45),HR 0·55(95%CI 0·39-0·78)。
- 辅助亚组因样本量小,结果无结论性。
- 190例死亡中157例(83%)死于膀胱癌进展;其他死因包括心血管事件8例(4%)、化疗毒性相关死亡4例(2%)、第二原发癌4例(2%)。
关键数值与推荐
- 围手术期总体人群:dd-MVAC组5年总生存64%(95%CI 58-70)vs GC组56%(95%CI 50-63),HRstrat 0·79(95%CI 0·59-1·05)。
- 围手术期总体人群:dd-MVAC组5年膀胱癌死亡累积发生率27%(95%CI 21-32)vs GC组40%(95%CI 34-46),HRstrat 0·61(95%CI 0·45-0·84)。
- 新辅助亚组:dd-MVAC组5年总生存66%(95%CI 60-73)vs GC组57%(95%CI 50-64),HR 0·71(95%CI 0·52-0·97)。
- 新辅助亚组:dd-MVAC组5年膀胱癌死亡累积发生率24%(95%CI 18-30)vs GC组38%(95%CI 32-45),HR 0·55(95%CI 0·39-0·78)。
临床怎么用
- 作者认为,数据支持在新辅助治疗中使用6周期dd-MVAC而非4周期GC。
- 作者认为这些结果应影响膀胱癌的临床实践及未来的免疫治疗试验。
- 围手术期总体人群中未发现dd-MVAC较GC改善总生存的证据。
局限性
- 辅助亚组因样本量小,结果无结论性。
- 围手术期总体人群中dd-MVAC组与GC组5年总生存差异的HRstrat 0·79(95%CI 0·59-1·05)未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal perioperative chemotherapy for patients with muscle-invasive bladder cancer is not defined. The VESPER (French Genito-Urinary Tumor Group and French Association of Urology V05) trial reported improved 3-year progression-free survival with dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) versus gemcitabine and cisplatin (GC) in patients who received neoadjuvant therapy, but not in the overall perioperative setting. In this Article, we report on the secondary endpoints of overall survival and time to death due to bladder cancer at 5-year follow-up. METHODS: VESPER was an open-label, randomised, phase 3 trial done at 28 university hospitals or comprehensive cancer centres in France, in which adults (age ≤18 years and ≤80 years) with primary bladder cancer and histologically confirmed muscle-invasive urothelial carcinoma were randomly allocated (1:1; block size four) to treatment with dd-MVAC (every 2 weeks for a total of six cycles) or GC (every 3 weeks for a total of four cycles). Overall survival and time to death due to bladder cancer (presented as 5-year cumulative incidence of death due to bladder cancer) was analysed by intention to treat (ITT) in all randomly assigned patients. Overall survival was assessed by the Kaplan-Meier method with the treatment groups compared with log-rank test stratified for mode of administration of chemotherapy (neoadjuvant or adjuvant) and lymph node involvement. Time to death due to bladder cancer was analysed with an Aalen model for competing risks and a Fine and Gray regression model stratified for the same two covariates. Results were presented for the total perioperative population and for the neoadjuvant and adjuvant subgroups. The trial is registered with ClinicalTrials.gov, NCT01812369, and is complete. FINDINGS: From Feb 25, 2013, to March 1, 2018, 500 patients were randomly assigned, of whom 493 were included in the final ITT population (245 [50%] in the GC group and 248 [50%] in the dd-MVAC group; 408 [83%] male and 85 [17%] female). 437 (89%) patients received neoadjuvant chemotherapy. Median follow-up was 5·3 years (IQR 5·1-5·4); 190 deaths at the 5-year cutoff were reported. In the perioperative setting (total ITT population), we found no evidence of association of overall survival at 5 years with dd-MVAC treatment versus GC treatment (64% [95% CI 58-70] vs 56% [50-63], stratified hazard ratio [HRstrat] 0·79 [95% CI 0·59-1·05]). Time to death due to bladder cancer was increased in the dd-MVAC group compared with in the GC group (5-year cumulative incidence of death: 27% [95% CI 21-32] vs 40% [34-46], HRstrat 0·61 [95% CI 0·45-0·84]). In the neoadjuvant subgroup, overall survival at 5 years was improved in the dd-MVAC group versus the GC group (66% [95% CI 60-73] vs 57% [50-64], HR 0·71 [95% CI 0·52-0·97]), as was time to death due to bladder cancer (5-year cumulative incidence: 24% [18-30] vs 38% [32-45], HR 0·55 [0·39-0·78]). In the adjuvant subgroup, the results were not conclusive due to the small sample size. Bladder cancer progression was the cause of death for 157 (83%) of the 190 deaths; other causes of death included cardiovascular events (eight [4%] deaths), deaths related to chemotherapy toxicity (four [2%]), and secondary cancers (four [2%]). INTERPRETATION: Our results on overall survival at 5 years were in accordance with the primary endpoint analysis (3-year progression-free survival). We found no evidence of improved overall survival with dd-MVAC over GC in the perioperative setting, but the data support the use of six cycles of dd-MVAC over four cycles of GC in the neoadjuvant setting. These results should impact practice and future trials of immunotherapy in bladder cancer. FUNDING: French National Cancer Institute.
引用
- Pfister C, Gravis G, Flechon A, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2023. PMID: 38142702. doi:10.1016/S1470-2045(23)00587-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。